Human Umbilical Cord Mesenchymal Stem Cell(UC-MSC)Delayed Renal Chronic Kidney Disease(CKD3、4 )
NCT05512988 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 44
Last updated 2022-08-23
Summary
The chronic kidney disease is caused by renal structural and functional impairment for more than 3 months due to various causes, including normal and abnormal glomerular filtration rate (GFR), abnormal blood, urine, and imaging findings, or an unexplained decline in GFR (\<60 ml/min). Recent years, the incidence of chronic kidney disease has increased year by year worldwide, the incidence of CKD is 8% to 16% in the world's total population. chronic kidney disease has become an important public health problem in China and even the world.
Summarizing the basic and clinical studies at home and abroad, inflammatory factors such as inflammatory chemokines, cytokines, and reactive oxygen species interact with fibrosis factors such as mesangial cells, fibroblasts, and fibroblast activation, which are the root causes of the progression of CKD and the formation of tubular interstitial fibrosis and glomerular sclerosis and developing into end-stage renal disease.
Current treatments for chronic kidney disease are very limited, and to be precise, there is currently no cure for chronic kidney disease, nor is there a proven way to improve the kidneys survive after acute kidney injury (AKI). The progression of the disease itself can only be delayed as much as possible by changing the diet, controlling related complications with oral medications (such as hypertension, hyperlipidemia, nephropathy, etc.), and actively controlling blood glucose and glycosylated hemoglobin levels in patients with diabetes. For patients with stage CKD5 and more severe, renal replacement therapy is recommended, including hemodialysis and peritoneal dialysis, but there are many complications in both dialysis methods, such as narrowing of the internal fistula, occlusion, catheter infection, peritonitis, etc. Kidney transplantation may be considered when economic conditions permit and there is a matching kidney source, but kidney transplant surgery is riskier. The above treatment methods have brought a heavy burden to patients and social medicine. In order to seek innovative and effective strategies to cultivate the limited regenerative capacity of the kidneys and reverse renal fibrosis, the mesenchymal stem cells (MSCs) with tissue regenerative potential and immunomodulatory functions have brought new ideas and hopes for the prevention and treatment of chronic kidney disease.
Conditions
- Chronic Kidney Diseases
Interventions
- BIOLOGICAL
-
UC-MSC
Usage: The stem cell preparation in this study is used intravenously in the elbow. Dose: The dose of stem cell injection in this clinical study is set at 1×10\^6/Kg/time per injection, and the injection frequency is 2 weeks/time. Duration: 2 injections per trial group for the entire duration of the course, with a total dose of 2×10\^6/Kg/person.
- BIOLOGICAL
-
Saline solution
Usage: The saline solution in this study is used intravenously in the elbow. Dose: The dose of saline solution in this clinical study is set at 250ml/time per injection, and the injection frequency is 2 weeks/time. Duration: 2 injections per person for the entire duration of the course
Sponsors & Collaborators
-
Zhongyuan Xiehe Biological Cell Storage Service (Tianjin) Co., Ltd.
collaborator UNKNOWN -
Tongji Hospital
lead OTHER
Principal Investigators
-
GANG XU · Tongji Hospital
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-13
- Primary Completion
- 2024-04-30
- Completion
- 2024-05-31
Countries
- China
Study Locations
More Related Trials
-
Evaluation of Thiosulfate Enhanced Organ Preservation Solution in Kidney Transplantation
NCT06288152 ·Status: RECRUITING ·Phase: NA
-
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
NCT02166489 ·Status: COMPLETED ·Phase: PHASE1
-
Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)
NCT02966717 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of KDSTEM Inj. in Patients With Chronic Kidney Disease
NCT06071143 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis
NCT05265325 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial of Mesenchymal Stem Cells in the Treatment of Severe Acute Kidney Injury
NCT04194671 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
16-Week Repeat Oral Dose Study of AKB-6548 for Anemia in Participants With End Stage Renal Disease (ESRD) Requiring Chronic Hemodialysis
NCT02260193 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I Study of Alpha-Melanocyte Stimulating Hormone in Patients With Acute Renal Failure
NCT00004496 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of GCS-100 to Treat Chronic Kidney Disease
NCT01717248 ·Status: COMPLETED ·Phase: PHASE1
-
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
NCT03596749 ·Status: UNKNOWN ·Phase: PHASE3
-
Medicine-induced Cardiac Hemodialysis on COVID-19
NCT05711810 ·Status: COMPLETED ·Phase: PHASE4
-
The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy
NCT06614985 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease
NCT06248567 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients
NCT05035641 ·Status: COMPLETED ·Phase: PHASE2
-
Dose-Titration Study of Sevelamer Carbonate in Chronic Kidney Disease (CKD) Patients on Hemodialysis
NCT01736150 ·Status: COMPLETED ·Phase: PHASE3
-
Phase II Randomized, Open-label, Multicenter Clinical Study Evaluating the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of SHR-2173 Injection in Patients With Primary Membranous Nephropathy
NCT07289763 ·Status: RECRUITING ·Phase: PHASE2
-
Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects
NCT05948059 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1
-
Study of YK012 in Primary Membranous Nephropathy
NCT06982729 ·Status: RECRUITING ·Phase: PHASE1
-
Long-Term Follow-up Study of Participants Exposed to Renal Autologous Cell Therapy Frozen Product
NCT06790498 ·Status: ENROLLING_BY_INVITATION
-
Fu-zheng-qu-zhuo Oral Liquid Improves Renal Function in Patients of CKD Stage 3 and 4
NCT02275468 ·Status: COMPLETED ·Phase: PHASE2
-
CKDu Treated With Intra-arterial Infusion of Autologous SVF Cells
NCT05154591 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease
NCT01460199 ·Status: COMPLETED ·Phase: PHASE1
-
Metabolism and Excretory of HSK21542 in Maintenance Hemodialysis Patients
NCT06238388 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease
NCT00742716 ·Status: COMPLETED ·Phase: PHASE2
-
An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
NCT06469190 ·Status: RECRUITING ·Phase: EARLY_PHASE1